Alder BioPharmaceuticals® to Present at the 36th Annual J.P. Morgan Healthcare Conference

BOTHELL, Wash., Jan. 03, 2018 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today announced that it will webcast its presentation at the upcoming J.P. Morgan Healthcare Conference at 4:00 p.m. PT (7:00 p.m. ET) on Monday, January 8, 2018 in San Francisco, CA. The presentation will feature a corporate overview and update by Randall C. Schatzman, Ph.D., president and chief executive officer.

A live audio webcast of the event can be accessed on the Events & Presentations page of the Investors section of Alder's website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder's website for at least 30 days after the live event concludes.

Presentation Link: https://jpmorgan.metameetings.net/events/healthcare18/sessions/13306-alder-biopharmaceuticals-inc/webcast

Q&A Link: https://jpmorgan.metameetings.net/events/healthcare18/sessions/13723-alder-biopharmaceuticals-inc-q-a/webcast

About Alder BioPharmaceuticals
Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company committed to transforming the treatment paradigm for patients with migraine and other serious neurological or inflammatory conditions. Leveraging its pioneering monoclonal antibody technologies, Alder discovers and develops novel therapeutic antibodies designed to deliver highly differentiated, best-in-class clinical profiles. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody administered quarterly via infusion that allows for 100% of the dose available to selectively and potently inhibit the calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more information, please visit http://www.alderbio.com.

Media Contacts:             
Ashley Cadle                     
TogoRun                            
(310) 463-0143
[email protected]

Investor Relations Contact:
Michael Schaffzin
Stern Investor Relations, Inc.
212-362-1200
[email protected]